RxDoctor Payments Data

Osaf Ahmed, MD

Internal Medicine · Chandler, AZNPI 1396775680

Payments from drug & device makers

$570in general payments, 2019–2025

Across 22 payments — averaging $25.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$150
  • Boehringer Ingelheim$70
  • AstraZeneca$59
  • Lilly USA, LLC$58
  • GSK$57
  • Irhythm Technologies, Inc.$38
  • plus $138 from 7 others

What the payments were for

  • Consulting fees$15026%
  • Speaking & faculty fees$356%
  • Food & beverage$38568%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$570 in reported general payments places this provider in the 65th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$40,302
Medicare patients
117
Services billed
366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$39,618
TrulicityDulaglutide31$28,292
EliquisApixaban37$24,418
JardianceEmpagliflozin29$21,938
FarxigaDapagliflozin Propanediol16$8,675
Breo ElliptaFluticasone/Vilanterol17$8,418
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,514
Rosuvastatin Calcium60$1,286
Atorvastatin Calcium92$1,204
Valsartan33$839
Lisinopril63$837
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide34$796
Allopurinol35$743
Gabapentin34$579
Losartan Potassium70$561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$58$28,29231 claims
PfizerEliquis$12$24,41837 claims
Boehringer IngelheimJardiance$70$21,93829 claims
AstraZenecaFarxiga$59$8,67516 claims
GSKBreo Ellipta$57$8,41817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →